ArticleiScience2026
Longitudinal ctDNA tracking by low-pass whole-genome sequencing predicts CAR-T outcomes in B-cell lymphomas.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Application Value of Liquid Biopsy in Cancer MRD Detection and the Preliminary Clinical Significance of the TFx Value.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current PET/CT monitoring for relapsed/refractory B-cell lymphomas treated with CAR-T therapy often lacks specificity. We evaluated longitudinal low-pass whole-genome sequencing (LP-WGS) of circulating tumor DNA (ctDNA) in 11 patients with B-cell lymphoma receiving axicabtagene ciloleucel to assess treatment response and prognosis. We found that lower baseline tumor fraction correlated with complete remission (CR), and ctDNA positivity at baseline or 1-month post-infusion significantly predicted inferior survival outcomes. Combining ctDNA with PET/CT refined risk stratification, distinguishing high-risk patients more accurately than imaging alone. Furthermore, specific genomic features, such as 17p deletion and high copy number variation burden, were associated with poor prognosis. We conclude that LP-WGS of ctDNA shows promise as a complementary tool to PET/CT for response evaluation and risk stratification in CAR-T-treated B-cell lymphomas, highlighting its potential to guide personalized clinical management in lymphoma care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.